Még nem toboroz
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Contact: Alexion Pharmaceuticals, Inc., Sponsor
Még nem toboroz
A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
NCT07941609· 2. fázis· AstraZeneca· Forrás
Toboroz
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
NCT07851025· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305· 3. fázis· AstraZeneca· Forrás
Contact: AstraZeneca Clinical AstraZeneca Clinical
Toboroz
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658· 2. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702· 2. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
NCT07222917· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608· 2. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926· 2. fázis· AstraZeneca· Forrás
Toboroz
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787· 2. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Contact: Alexion Pharmaceuticals, Inc. (Sponsor)
Toboroz
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· 3. fázis· AstraZeneca· Forrás
Toboroz
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261· 3. fázis· AstraZeneca· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197· 2. fázis· AstraZeneca· Forrás
Toboroz
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449· 3. fázis· AstraZeneca· Forrás
Toboroz
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Toboroz
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864· 3. fázis· AstraZeneca· Forrás
Contact: AstraZeneca Breast Cancer Study Locator Service
Fut, nem toboroz
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
NCT05692180· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
NCT04606771· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235· 3. fázis· AstraZeneca· Forrás
Showing 50 of 56.